StockVS

NASDAQ · USD

Cingulate Inc. (CINGW) Stock Analysis

Cingulate Inc. (CINGW) is a stock listed on NASDAQ and quoted in US Dollar.

CINGW

$0.01

−$0.00 (−0.88%)

Sep 4, 2026 · Market close

This is a derivative instrument — a warrant on Cingulate Inc. (CING) common stock.

Issuer fundamentals are shown on the issuer page, not here.

View CING →

Price History

Hover for the daily close. The dotted line marks the period open.

CINGW Key Statistics

As of Sep 4, 2026
Trading
Open
$0.04
Previous Close
$0.01
Day's Range
0.01–0.01
52-Week Range
0.01–0.01
Volume
101
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.89

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CINGW Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−78.87%
2025 (partial year)+0.00%

As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

About Cingulate Inc.

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Visit website →